BlackRock Portfolio Management LLC filed an amended beneficial ownership statement with the SEC on October 27, 2026, disclosing an 8.1 percent stake in Fulcrum Therapeutics Inc as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock Portfolio Management LLC reported holding 6,155,437 shares of Fulcrum Therapeutics common stock.
  • Percent of class: The reported position represents 8.1 percent of the outstanding common shares.
  • Sole voting power: BlackRock Portfolio Management LLC holds sole voting power over 5,436,791 shares.
  • Sole dispositive power: The firm holds sole dispositive power over all 6,155,437 shares, with no shared dispositive power reported.
  • Event date: The filing event triggering this statement occurred on September 30, 2026.
  • Certifying officer: Spencer Fleming, Managing Director, signed the statement on October 27, 2026.

BlackRock Portfolio Management's Position in Fulcrum Therapeutics as of September 30, 2026

According to the filing, BlackRock Portfolio Management LLC, a Delaware-organized entity headquartered at 50 Hudson Yards, New York, NY 10001, reported an aggregate beneficial ownership of 6,155,437 shares of common stock in Fulcrum Therapeutics Inc (NASDAQ:FULC), a clinical-stage biopharmaceutical company located at 26 Landsdowne Street, Cambridge, MA 02139. The statement is an amendment (Amendment No. 1) to a prior Schedule 13G filing, with the qualifying event date listed as September 30, 2026.

The filing discloses that BlackRock Portfolio Management LLC holds sole voting power over 5,436,791 shares and sole dispositive power over the full 6,155,437 shares, with zero shared voting or dispositive power in either category. The firm noted that the securities covered by this report reflect ownership by certain business units described as "Reporting Business Units" of BlackRock, Inc. and its subsidiaries and affiliates, consistent with SEC Release No. 34-39538 dated January 12, 1998. The filing further states that the report does not include securities, if any, beneficially owned by other BlackRock business units whose beneficial ownership is disaggregated from that of the Reporting Business Units under that release.

Regarding the right to receive dividends or sale proceeds, the filing states that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of FULCRUM THERAPEUTICS INC," and that no single person's interest exceeds five percent of the total outstanding common shares. The filing is classified under reporting person type "HC" and was certified by Spencer Fleming as Managing Director of BlackRock Portfolio Management LLC.

What Was Disclosed

BlackRock Portfolio Management LLC filed an amended beneficial ownership statement covering 6,155,437 shares, equal to 8.1 percent, of Fulcrum Therapeutics Inc common stock (CUSIP 359616109), based on holdings as of September 30, 2026, and signed October 27, 2026.